Mapp Biopharmaceutical

14 articles about Mapp Biopharmaceutical

• DCN Dx and Mapp Biopharmaceutical Announce Subcontract

  2/1/2023

  DCN Dx announced a subcontract with Mapp Biopharmaceutical, Inc., a developer of novel pharmaceuticals for the prevention and treatment of infectious diseases, focusing on unmet needs in global health and biodefense.

• Aridis Signs Exclusive Terms to Secure Worldwide Commercial Licenses for Pan-Ebola and Pan-Marburg Monoclonal Antibody Programs from Mapp Biopharmaceutical

  12/5/2022

  Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, signed an exclusive term sheet to secure international development and global commercial rights upon licensure for the pan-Ebola and pan-Marburg monoclonal antibody (mAbs) programs from Mapp Biopharmaceutical, Inc.

• 

  What's New in the Biodefense Market These Days?

  2/4/2019

  Although bioterrorism doesn’t get the kind of attention more traditional bombings and shootings receive, the biotech industry and the federal government are paying attention and actively funding and developing countermeasures to potential bioterror, military and public health emergencies.
• 

  As Deadliest Strain Ravages Country, Four Experimental Ebola Vaccines to Be Deployed in the Congo

  11/12/2018

  As an outbreak of the Ebola virus in the Democratic Republic of the Congo worsens, a team of health officials has taken four experimental vaccines to the front lines and begun to administer it to patients who may have been exposed to the deadly virus.

• ClinicalRM (formerly known as Clinical Research Management) And Mapp Biopharmal Combine Efforts To Continue The Fight Against Ebola

  8/9/2016

• Mapp Biopharma Scientists Try To Stop Another Deadly Virus

  4/5/2016

• Nascent Biotech Announces $225,000 NIH Grant Award In Conjunction With Mapp Biopharmaceutical

  2/26/2015

• Drugmakers Like Johnson & Johnson, Emergent BioSolutions, And Mapp Biopharmaceutical Stand To Gain Ebola Contracts Worth $2 Billion

  11/11/2014

• Ebola Clinical Trials: Big Name Players In The Ebola Race

  10/28/2014

• U.S. Regulators Ask Three Labs For Mapp Biopharmaceutical's ZMapp Ebola Plans

  10/20/2014

• Amgen Will Assign 12 To 14 Staff Members To Look Into An Alternative Production Method For Mapp Biopharmaceutical's ZMapp

  10/20/2014

• Mapp Biopharmaceutical's Ebola Drug Production Set for Texas, Possibly North Carolina

  9/30/2014

• Feds To Provide As Much As $42.3 Million To Tiny San Diego-Based Mapp Biopharmaceutical

  9/3/2014

• "Plantibodies" Drugs Made From Small Biotechs Like Mapp Biopharmaceuticals Advance As Big Pharma Stands Aside

  8/18/2014